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ABSTRACT.  Protein-protein interactions (PPIs) have emerged as important targets for 
pharmaceutical intervention because of their essential role in numerous physiological and 
pathological processes, but screening efforts using small-molecules have led to very low hit 
rates. Linear peptides could represent a quick and effective approach to discover initial PPI hits, 
particularly if they have inherent ability to adopt specific peptide secondary structures. Here, we 
address this hypothesis through a linear helical peptide library, composed of four sub-libraries, 
which was designed by theoretical predictions of helicity (Agadir software). The 13-mer peptides 
of this collection fixes either a combination of three aromatic or two aromatic and one aliphatic 
residues on one face of the helix (Ac-SSEEX
5
ARNX
9
AAX
1 2
N-NH2) , since these are 
structural features quite common at PPIs interfaces. The 81 designed peptides were conveniently 
synthesized by parallel solid-phase methodologies, and the tendency of some representative 
library components to adopt the intended secondary structure was corroborated through CD and 
NMR experiments. As proof of concept in the search for PPI modulators, the usefulness of this 
library was verified on the widely studied p53-MDM2 interaction and on the communication 
between VEGF and its receptor Flt-1, two PPIs for which a hydrophobic α–helix is essential for 
the interaction. We have demonstrated here that, in both cases, selected peptides from the library, 
containing the right hydrophobic sequence of the hot-spot in one of the protein partners, are able 
to interact with the complementary protein. Moreover, we have discover some new, quite potent 
inhibitors of the VEGF-Flt-1 interaction, just by replacing one of the aromatic residues of the 
initial F
5
Y
9
Y
12
 peptide by W, in agreement with previous results on related antiangiogenic 
peptides. Finally, the HTS evaluation of the full collection on thermoTRPs has led to a few 
antagonists of TRPV1 and TRPA1 channels, which open new avenues on the way to innovative 
modulators of these channels. 
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INTRODUCTION  
Protein-protein interactions (PPIs) are ubiquitous in biological systems and play pivotal roles 
in key biological processes.
1
 Therefore, while aberrant, inappropriate or poorly regulated 
interactions might cause various diseases, the ability to interfere with specific PPIs can provide 
attractive opportunities for therapeutic intervention.
2-4
 Progress in recent years has shown that 
protein-protein interfaces are more tractable than had initially been thought and diverse PPI 
inhibitors have been reported.
5-8 
In this regard, the pioneering work of Clackson and Wells, 
defining the "hot spots" as bimolecular interface residues that contribute mostly to the free 
binding energy
 
of PPIs, has been a major conceptual advance.
9
 On this basis, disruptors or 
stabilizers of PPIs do not need to mimic the entire protein surface, but rather a smaller subset of 
key residues and, consequently, peptides, peptidomimetics and small molecules could be used 
for modulating these interactions. An attractive strategy is the design and synthesis of 
compounds able to imitate the conformation and electronic properties of the functional epitopes 
at native protein interfaces, mimicking elements of protein secondary structures.
11,12
 In this 
sense, conformationally defined peptide libraries have successfully been used to identify new 
PPI modulators,
13,14
 and constituted the first step toward non-peptide secondary structure 
mimetics.
15-18
 
α-Helices, the largest class of secondary structure elements of proteins, mediate a plethora of 
highly specific protein-protein interactions.
19
 In some of these protein complexes, just one face 
of the α-helix is involved in binding, with important residues for affinity displayed at i, i+3(i+4) 
and i+7 relative disposition.
20
 Quite frequently, the key contacts between these helical motifs 
and the complementary binding sites are mediated by hydrophobic residues at the indicated 
positions. For instance, the 19-25 peptide fragment of the pro-apoptotic protein p53 forms an 
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amphipathic α-helix in its interaction with MDM2, being Phe19, Trp23 and Leu26 crucial 
interacting residues.
21
 HIV-1 envelope glycoprotein gp41 displays a challenging intramolecular 
protein–protein interaction that is mainly mediated by the Trp628, Trp631, and Ile635 residues on an 
α-helix of the CHR domain.22 Within the 17–25 VEGF-A fragment, a Phe17 residue has been 
identified as key for the interaction of this growth factor with its Flt-1 and KDR receptors 
(VEGFR1 and VEGFR2), while Tyr
21
 and Tyr
25
 seem to be important for the stabilization of the 
α-helical structure.23 In epoxide hydrolase oligomers, clusters of aromatic residues commonly 
participate in the protein–protein interactions, as deduced from computational analysis.24 
PPIs are also essential in ion channels, where multimeric transmembrane-spanning proteins 
interact to form the channel pore, and diverse accessory proteins contribute to regulate their 
function.25,26 In addition, ion channels are substrates for different protein kinases and 
phosphatases that regulate channel gating, bind G protein β,-heterodimers, or interact with 
Calmodulin (CaM), an ubiquitous calcium sensor protein, among many others. Recent structural 
studies reveal a central role of α-helix secondary structures, as well as of particular hydrophobic 
interactions, in the formation and stabilization of protein-protein complexes involving ion 
channels.
27-31  
Thermosensory channels (thermoTRPs), belonging to the family of transient receptor potential 
(TRP) channels, are activated by a variety of environmental temperatures, from noxious (<15°C, 
TRPA1) to innocuous cold (<28°C, TRPM8), and to injurious heat (52°C, TRPV1), and 
contribute to the thermal hypersensitivity under painful conditions.
32,33
 Additionally, 
thermoTRPs are also implicated in the physiopathology of several diseases, like inflammation, 
asthma, and certain cancers.
32-34
 All this facts have trigger intensive drug discovery programs 
aimed at developing new modulators of these channels, especially of TRPV1.
33,35
 However, after 
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remarkable investment and a plethora of molecules, the clinical trials with TRPV1 antagonists 
have mostly been disappointing due to unpredicted side effects, while the development of 
modulators of other TRP channel is still in its infancy.
33
 Therefore, there is a need for new 
approaches to TRP channel modulators with alternative mechanisms of action. In this respect, we 
have recently described short peptides (TRPducins), mapping the sequence of TRPV1 TRP 
domain, which were able to block selectively the channel, probably by disrupting protein-protein 
interactions at the cytosol.
36 
General chemical strategies for finding PPI modulators include α–helix-derived constrained 
peptides (through covalent disulfide, lactam bridges, hydrocarbon stapling and HSB cyclization 
methods), foldamers (β- and mixed α/β-peptides) and proteomimetics (terphenyl, and their 
related heterocyclic and amide α–helix-mimetics).12-19,37,38 All these strategies, which usually 
require elaborated chemistry, have been successfully applied to PPIs with known interfaces.
37
 
Within this context, linear peptide-based libraries have been much less explored, because these 
peptides generally adopt random conformations that could prevent their binding to protein 
partners.
39-41
 However, if linear peptides had a certain tendency to be helical, they would be able 
to adopt the right 3D structure by an induced fit mechanism during the interaction. This, 
combined with the inherent degree of flexibility, makes linear peptides ideal for the discovery of 
primary modulators of topographically diverse, unknown PPIs. 
In view of the considerations above, we proposed the preparation of a linear peptide library as a 
versatile tool towards PPI modulators. Peptides within this library should show a tendency to 
adopt helical conformations, and to have at least three hydrophobic amino acids conveniently 
located at one side of the helical structure. This article provides details on the de novo design of 
this library, its solid-phase parallel synthesis and the conformational characterization of a few 
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components. Moreover, the ability of some components of this library to modulate protein-
protein interactions has been validated in a couple of known PPIs, p53-HDM2 and VEGF-
VEGFR-1. In both PPI systems the existence of a hydrophobic face on one helix is crucial for the 
molecular recognition by the target protein. Finally, the evaluation of the full library on 
thermoTRPs has permitted the identification of a few peptides able of inhibiting the activation of 
TRPV1 and TRPA1 channels. 
RESULTS AND DISCUSSION 
De Novo Design. PPIs are mainly driven by the hydrophobic effect,
42
 and quite frequently the α-
helix secondary element is involved within protein-protein interfaces. Therefore, helical peptides 
with appropriately located aromatic and aliphatic hydrophobic residues could serve to discover 
new PPI modulators. To guarantee at least three points of interaction, peptides containing three 
aromatic or two aromatic and one aliphatic residues were designed. The length of the peptide 
should assure the possibility of three turns for situating key residues on the same helix face (i, 
i+4, i+7, relative positions). Using Agadir software,
43
 we started by predicting the helicity of the 
12-mer peptide Ac-AAAF
4
AAAF
8
AAF
11
A-NH2 (11.9% helicity) and four analogues containing 
E(D) and K(R) at positions 2 and 6 to stabilize the helix through saline bridges (opposite face to 
the aromatic F residues). Peptide Ac-AEAF
4
ARAF
8
AAF
11
A-NH2, with the highest helicity 
(24.8%), was selected as the starting point to study the best residues for the non-highlighted 
positions. With this aim, we generated virtual libraries in which each Ala residue was replaced 
by the other 19 proteinogenic amino acids. Computational predictions of helicity on each library 
component allowed the selection of those residues that lead to higher helicity than Ala (see 
supporting information for details), which were then considered and combined for the next 
generation of virtual libraries. Since the solubility of peptides over six residues is normally a 
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limiting factor, theoretical solubility (calculated with ALOGPS
44
) was also taken into account to 
discriminate among certain amino acids. Finally, the addition of an additional residue, either at 
N- or C-terminal, was considered to balance helicity and solubility. This process resulted in the 
final design of 13-mer peptide sub-libraries L1-L4, as candidates for synthesis (Table 1). Library 
L1 is the result of all possible combinations of the three aromatic amino acids (Phe, Trp, Tyr) at 
positions 5, 9 and 12, while collections L2-4 mix up two aromatic (from Phe, Trp, Tyr) and one 
aliphatic (from Leu or Ile) residues at these positions. Ranges of helicity predicted for these 
libraries are included in Table 1. 
Table 1. Designed sub-libraries of helical peptides 
Library 
(#Compd) 
Sequence
a
 % Helicity
b
 
L1 
(27) 
SSEEAr
5
ARNAr
9
AAAr
12
N 35-65 
L2 
(18) 
SSEEAl
5
ARNAr
9
AAAr
12
N 27-55 
L3 
(18) 
SSEEAr
5
ARN Al
9
AAAr
12
N  32-46 
L4 
(18) 
SSEEAr
5
ARNAr
9
AA Al
12
N  33-58 
a
 All peptides are acetylated at N-terminal and amidated at C-terminal. Ar = aromatic amino 
acids F, W, and Y; Al = aliphatic amino acids I, and L. 
b
 Calculated by Agadir. 
 
Synthesis of Peptide Libraries. Sub-libraries L1-L4 (81 peptides) were individually prepared 
using parallel solid-phase methodologies (Fmoc/tBu strategy). Peptides were elongated on a 
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Rink amide resin, either manually or in a microwave-coupled peptide synthesizer, using HCTU 
and HBTU/HOBT, respectively, as coupling agents. Peptides were acetylated at N-terminal 
before cleavage from the resin with TFA/EDT/H2O/TIPS (94:2.5:2.5:1). After precipitation with 
ethyl ether and liophylization, compounds obtained with purity lower than 80% were purified by 
MPLC on reverse-phase cartridges or by semipreparative RP-HPLC-MS in difficult cases. Yield 
of L3 compounds were lower than those of the other sub-library components, due to unexpected 
difficult couplings of the Arg residue, resulting in mixtures of the desired peptide and Arg-
deletion analogues. All final peptides were characterized by MS spectrometry, and a few 
components also through exact mass measurements (Tables S1-S4). 
Conformational Studies. Several peptides were randomly selected for conformational studies 
in solution to evaluate their ability to adopt helical structures. 
CD Experiments. The predisposition of the chosen peptides to adopt helical conformations 
was first checked by circular dichroism (CD). All CD spectra displayed the helix-characteristic 
double minimum at 208 and 222 nm (Figures 1 and S1-S5). As shown in Table 2, selected 
peptides showed significant helix populations in aqueous solution (20%). This percentage was 
considerably increased in the presence of the structure-inducing cosolvent TFE (up to 47%), 
symptomatic of their high propensity to be helical in a suitable environment. 
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Table 2. Experimental CD helicity of selected peptides Ac-SSEEX
5
ARNX
9
AAX
1 2
N-NH2  
Compd.
 a 
X
5
X
9
X
12
 
% Helicity 
H2O 30% TFE 
FWF 22 40 
LWW 19 41 
IWY 23 28 
FIY 26 38 
WIW 28 44 
YWL 30 47 
a 
The notation indicates residues at positions 5, 9 and 12 of the peptide sequence. 
 
Figure 1. CD spectra of peptide F
5
W
9
F
12
 in H2O and 30% TFE/H2O at pH 5.5 and 5ºC. 
 
NMR studies. Four of the randomly selected peptides were shown to adopt helical structure by 
1H NMR in TFE/H2O solutions. It is known that he 
1Hα chemical shifts depend on the  and  
dihedral angles,
45
 and negative values of conformational shifts ( observed – random 
coil,
46
 ppm) are characteristic of helical structures. In agreement with that, all peptides showed 
the expected profile for the Hα protons , with negative values for almost all residues in the 
sequence, except for the first Ser residue (Figure 2, and S6-S8). 
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As frequently found in linear helical peptides,  absolute values of central residues are larger 
than those at the N-terminal position, indicating that the helices are slightly less coiled at this end 
(Figures 2 and S6-S8). Further NMR studies with peptide I
5
W
9
Y
12
, namely 
13
C- and NOESY 
experiments, definitely corroborated the α-helix conformation. Thus, we obtained positive values 
for the of Cαchemical shifts (Figure S9), and a set of non-sequential NOEs (dαN(i, i+3), dαN(i, i+4) 
and dαβ(i, i+3), Figure 2, and S10-S11), both characteristic of helical structures. Using the 
intensities of the non-sequential NOEs as a restriction, we performed molecular dynamic 
calculations (CYANA program) to elucidate the structure of this peptide in solution, which 
adopts a well defined α-helix 3D conformation, with residues 5, 9, and 12 aligned along a single 
face of the helix (Figures 3 and S12). 
 
Figure 2.  Histogram showing the ΔδHα values (ΔδHα = δHαobserved – δHαRC, ppm) as a function 
of sequence number, and NOE summaries of peptide I
5
W
9
Y
12
 (30% TFE at 25ºC). N- and C-
 11 
termini are, respectively, in acetylated and amidated form, respectively. The thickness of the 
lines indicates the intensities of the sequential NOEs, i.e., strong, medium, weak. 
 
Figure 3. Solution NMR structure of the peptide I
5
W
9
Y
12
, side view (up) and viewed from above 
(down). Residues at positions 5, 9 and 12 are colored in green and orange. Hydrogen atoms and 
other side-chains are not shown.  
 
Validation as PPI modulators. Before exploring the usefulness of our library in the search for 
new inhibitors of poorly documented PPIs, we considered pertinent to validate it on well known 
models. For this purpose, we selected p53-MDM2 and VEGF-VEGFR1, because aromatic and 
aliphatic residues within a helical structure have been defined as key for the recognition process. 
p53-MDM2. The activity of p53, a tumor suppressor protein, is regulated by interaction with 
other proteins, including the ubiquitin ligase MDM2.
47
 This system has extensively been studied, 
and a number of structurally diverse molecules are able to inhibit the p53-MDM2 interaction, 
triggering either cell-cycle arrest or apoptosis in cancer models, without affecting healthy cells.
48-
50
 MDM2 binds p53 mainly through hydrophobic interactions, with a short helix of p53 
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positioned in the MDM2 binding cleft. Phe
19
, Trp
23
, and Leu
26
, located on the same side of the 
amphipathic p53 helix, are crucial contributors to the free energy of interaction, making direct, 
deep contacts in the binding cavity.
51
 Here we were not looking for new inhibitors, since several 
potent α- and β-peptide MDM2 antagonists (linear and stapled) have already been described.52-55 
Our aim was the use of the p53-MDM2 system as a proof of the validity of our library in the 
search of PPI modulators. Thus, peptide F
5
W
9
L
12
, which is supposed to align the key residues of 
p53 along one face of the helical structure, was selected to evidence its potential interaction with 
MDM2. Saturation transfer difference (STD) NMR experiments were performed to this end.
56,57
 
For comparison, some other peptides, namely F
5
L
9
W
12
, W
5
L
9
F
12
, and W
5
F
9
L
12
, having scramble 
disposition of key residues, were also evaluated. As shown in Figure 4, peptide F
5
W
9
L
12
 was 
able to interact with the HDM2 protein. In addition, peptide W
5
L
9
F
12
 showed also some STD 
effects, but weaker than the p53-related F
5
W
9
L
12
 (relative STD effect, ηsat, received by the two 
peptides was 7.9 and 5.1 %, respectively). On the contrary, F
5
L
9
W
12
 and W
5
F
9
L
12
 analogues 
elicited lower STD effects upon saturation of the protein (ηsat < 5%). The STD spectrum of the 
FWL-MDM2 complex allows the qualitative identification of protons from the peptide at the 
MDM2 interface. Thus, the signals corresponding to some protons of aromatic residues (7.0-7.5 
ppm region) and those of Leu methyl groups (< 1 ppm) can clearly be distinguished, among 
other protons of F
5
W
9
L
12
 peptide. This result suggests the direct implication of Phe, Trp and Leu 
residues of our peptide on the interaction with the protein, probably mimicking the p53 helix and 
occupying the same pocket. 
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Figure 4. 1D proton spectrum of peptide F
5
W
9
L
12
 (0.5 mM)/MDM2 (0.025 mM) complex (a). 
The corresponding STD NMR spectrum recorded upon saturation at –1 ppm (b). 
 
VEGF-VEGFR1. Vascular Endothelial Growth Factor (VEGF), has different isoforms. 
Among them, VEGF-A, a key protein in promoting angiogenesis, exerts its biological actions 
through binding to specific receptors VEGFR-1 (Flt-1) and VEGFR-2 (KDR).
58
 The α–helical 
fragment VEGF17-25, located at the N-terminal part of VEGF, has been identified as a main hot-
spot for the interaction with VEGFR-1. Within this helix, Phe
17
 residue seems crucial for the 
molecular recognition between the two proteins, while Tyr
21
 and Tyr
25
 appear more important for 
the stabilization of the secondary structure.
59
 In a recent paper, we described that 13-mer linear 
and cyclic peptides derived from the 17-25 VEGF fragment, and structured as α-helices in 
solution, were able to bind the Flt-1 receptor with micromolar affinity.
60
 Related longer helical 
peptides, in which the Phe residue has been substituted by Trp, have been described by 
D’Andrea et al. to show either pro- or anti-angiogenic properties.61,62 Since peptide F5Y9Y12 
from sub-library L1 has a similar arrangement of key aromatic residues than VEGF17-25, its 
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hypothetical interaction with Flt-1 could represent an additional validation of our library. 
Although the third aromatic residue in our peptides is not exactly at the same relative position 
than in p53, the three aromatic amino acids are on the same face of the helix and could imitate 
the helical fragment in the native protein. Furthermore, we have already shown that cyclic 
peptides with only two aromatic residues YY or Y/Aromatic motif, without any amino acid 
between the two aromatic residues, are also able to inhibit the VEGF-Flt-1 interaction.
63 
Therefore, peptide F
5
Y
9
Y
12
, and some analogues containing a single point mutation at 5, 9, or 12 
position, were evaluated for their ability to displace biotinylated VEGF165 bound to the 
extracellular domain of recombinant Flt-1 (Table 3). In this assay, all peptides with three 
aromatic residues at the indicated positions (100 M) inhibited the binding of btVEGF165 to Flt-
1 receptors. The model FYY peptide, with a displacement of about 30% at 100 µM, was the 
weaker modulator of the VEGF-Flt-1 interaction, while the substitution of some of its key 
residues by Trp afforded more potent inhibitors of this PPI (45-50% inhibition at 100 µM). In 
particular, FWY and FYW peptides are among the most potent Flt-1 peptide binders described to 
date (Table 3, Figure 5).
63-65
 Moreover, the change of the central Tyr
9
 by a Phe residue slightly 
improve the inhibitory capacity with respect to the model peptide, while replacement of Tyr
12
 
residue by an aliphatic isoleucine led to an inactive peptide. For those peptides with an inhibition 
percentage greater than 35% at 100 µM, we perform experiments of dose-response relationships, 
observing that the magnitude of the response (the efficacy) is always comprised between 60 and 
70 % (Fig. 5). The relative IC50 values corroborated the initial results and confirm the beneficial 
effects of the substitution of individual Tyr residues of F
5
Y
9
Y
12
 peptide by Trp (Table 3).
63-65
 
These data confirmed the interaction of FYY peptide with Flt-1, giving support to the general 
interest of the library described here. In addition, the evaluation of some analogues of sub-library 
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L1 has uncovered novel potent modulators of this receptor, which deserve further 
pharmacological characterization, and could be the starting point to develop α–helical mimetics 
to interfere with the VEGF-Flt-1 interaction. 
In is worth noting that although all assayed peptides have a hydrophobic side, not all were able 
to interact with Flt-1 and not all are recognized by the same extent, indicating certain selectivity. 
Therefore, this kind of library could be of interest to study PPIs for which key interacting 
residues are unknown, and could provide valuable clues regarding important side-chains at PPI 
interfaces. 
 
Table 3. Inhibitory potency of selected peptides on Flt-1. Displacement assays. 
Compd. 
X
5
X
9
X
12
 
% Inhibition
a
 IC50
b
(µM)
 
FYY 29 ± 3 ND
c
  
FYW 48 ± 6 29 ± 5 
FWY 50 ± 5 23 ± 4 
WYY 45 ± 4 >100 
FFY 39 ± 6 >100 
YYY 33 ± 4 ND 
FYI 0 ND 
QK
d
 69 ± 3 32 ± 8
d
 
a 
Activity corresponds to the percentage of biotinylated VEGF165 displaced by a 100 µM 
concentration of peptide on the whole extracellular domain (ECD, D1-D7) of Flt-1 (this study). 
b
Relative inhibitory concentration 50 (concentration required to bring the curve down to point 
half way between the top and bottom plateaus of the curve). 
c
ND = Not determined. 
d
Described 
Flt-1-binder peptide, Ac-KLTWQELYQLKYKGI-NH2  (from references 60 and 63). 
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Figure 5. Dose-response curves for F
5
W
9
Y
12
 and F
5
Y
9
W
12 
peptides on Flt-1 displacement 
assays. Curves were fitted with log(Inhibitor) vs. response method using GraphPad Prism. When 
hill slope is fixed at 1, r
2
 are respectively 0,956 and 0,945 for F
5
W
9
Y
12
 and F
5
Y
9
W
12 
peptides. 
 
Effects on ThermoTRP Channels.  From our previous work,
36
 we knew that the most active 
TRPducing peptide, TRP-p5, has a sequence that resembles that of amphipathic helical peptides. 
Additionally, the TRP domain of the different transient potential receptor channels contains 
various sets of hydrophobic residues, some forming the coiled-coil necessary for channel 
assembly, and others supposedly implicated in channel activation.
66,67
 Site-directed mutagenesis 
studies have also revealed the functional importance of aromatic amino acid clusters at different 
locations of channel monomers.
68 
Inspired by the results of TRPducings,
36
 and by the above structural and functional facts, we 
decided to evaluate our library of helical peptides on TRPV1, TRPM8 and TRPA1 channels in 
the search for allosteric modulators. We were interested in exploring protein-protein interactions 
occurring during channel formation and/or gating. Thus, all components of our library (L1-L4) 
were assayed on these three channels, stably expressed in the appropriate cell lines (see SI for 
details). The agonist-induced intracellular Ca
2+
 signals were measured by microfluorography, 
using a fluorescence plate reader. While most library components, added at a 5 µM 
concentration, did not display blockade activity (<15%) at any of the assayed TRP channels, a 
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few Tyr-containing peptides blocked TRPV1 and/or TRPA1 activity in a significant manner 
(>20%, Table 4). None of the peptides showed activity at TRPM8 channels. Note that the best 
TRPV1 blockers have the aliphatic amino acid in the central position, but these peptides did not 
show selectivity with respect to TRPA1 receptors, being almost equipotent in both channels. 
Curiously, just displacing the aliphatic residue toward C-terminus resulted in TRPA1 selective 
compounds. Notably, peptides W
5
Y
9
I
12
, Y
5
F
9
L
12
 and Y
5
Y
9
I
12
 showed >50% blockade activity at 
5 µM. These peptides could serve as model for the development of peptidemimics able to 
reproduce the 3D disposition of the two aromatic and the aliphatic side chains within the helical 
structure.
37
 Since these peptides do not share either the structural requirements found in pore 
blockers, normally positively charged compounds,
69
 or the chemical composition of competitive 
small-molecule antagonists,
35
 it is possible that they act at PPIs related to channel formation or 
modulation by other proteins. 
Table 4. Peptides able to block significantly TRPV1 and TRPA1 channels 
Compd. 
X
5
X
9
X
12
 
TRPV1 
blockade 
(%)
a,c
 
TRPA1 
blockade 
(%)
b,c
 
FLF 23,93 ± 3.86 26,05±5,96 
YLF 25,61 ±5,6 24,03±10,93 
YIY 24,09 ±3.56 17,95±3,06 
YLY 38,03 ±4,39 37,34±5,71 
WYI 28,18 ±4,23 55,51±11,29 
YFL 19,77 ±3,71 51,18±10,21 
YYI 18,63 ±3,33 51,38±9,80 
a
 Blockade of capsaicin-induced Ca
2+
 entry trough TRPV1 channel by peptides. 
b
 Blockade of 
allyl isothyocyanate-induced Ca
2+
 entry trough TRPA1 channel by peptides. 
c
 Peptides were 
assayed at 50 and 5µM. 
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CONCLUSIONS 
Since PPIs are usually mediated by interactions between defined elements of peptide 
secondary structure, the search for modulators of these interactions could be speeded by testing 
libraries of easily prepared linear peptides, provided they are able to adopt these particular 
conformations. In this respect, we have used theoretical predictions to design a collection of 
linear peptides with a priori intrinsic ability to adopt helical conformations. In addition, they 
possess aromatic or combinations of aromatic/aliphatic residues conveniently located at one face 
of the intended helix, since this arrangement is quite common in PPI interfaces. After solid-phase 
synthesis, CD and NMR studies demonstrated the ability of these peptides to adopt the 
anticipated helical conformation in solution. 
Notably, specific member of the library were able to interact with proteins implicated in well 
known PPIs of therapeutic importance, thus validating the utility of the library in the search for 
PPI modulators. Thus, STD NMR experiments confirmed that peptide F
5
W
9
L
12
 associates with 
HDM2, one partner of the pro-apoptotic protein p53, implicated in tumor cell suppression. The 
interaction was tighter for the indicated peptide, which contains the same disposition of the 
hydrophobic residues as the p53 hot spot responsible for HDM2 binding, than for related 
analogues with a changed arrangement of these residues. In the same way, peptide F
5
Y
9
Y
12
, 
imitating key residues of an α–helix crucial for the molecular recognition between VEGF and its 
receptor Flt-1, was able to bind to this receptor. Remarkably, some Trp-containing analogues 
from sub-library L1 are among the most potent Flt-1 peptide binders reported to date. All these 
findings emphasize the usefulness of these linear helical peptides in the search for PPI 
modulators. 
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The library was also assayed for activity at three TRP channels, namely TRPV1, TRPM8 and 
TRPA1 thermoTRPs, given that certain domain segments of these channels are involved in 
several PPIs that participate in their regulation. Some peptides were able to inhibit the activation 
of TRPV1 and especially TRPA1 (W
5
Y
9
I
12
, Y
5
F
9
L
12
 and Y
5
Y
9
I
12
). Although the exact 
mechanism of action of these peptides remains to be determined, the TRPA1-interacting peptides 
described here could represent a first step toward the development of innovative non-peptide 
TRPA1 antagonists. 
We expect that this library of linear helical peptides could have broad application as tool to 
interrogate pharmacologically relevant PPI targets. Further studies on other known and 
unrevealed PPIs will show whether this library of easily prepared peptides could have wider 
practical application. In addition, the rational of design used here could also serve to fine-tune 
the potential of helical peptides implicated in PPIs, when extracted from their native proteins, 
and to ideate new libraries bearing other combinations of amino acids. 
EXPERIMENTAL PROCEDURES 
Parallel Synthesis of Peptides. Peptides were prepared starting from a Rink amide resin (0.34 
g/mol) following the Fmoc/ 
t
Bu strategy.  
Manual synthesis was performed repeating the cycle described below for each amino acid: 
First, resin was swelled with DMF and DCM (1ml/100mg of resin, 30 seconds x 4). Fmoc 
deprotections were performed with 20% piperidine in DMF (1 mL/100 mg of resin, one wash for 
1 min and three for 10 min). Coupling reactions were carried out with HCTU (2 equiv), DIEA (2 
equiv) and the corresponding Fmoc amino acid (2 equiv) in DMF for 1 h to obtain the peptides.  
Each coupling was checked by the Kaiser test and repeated if necessary.  
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Automated synthesis was performed using a peptide synthesizer coupled to a microwave 
heater (Cem Liberty1): resin was swelled with DCM for 10 min. Fmoc deprotections were 
performed with 20% piperidine in DMF in two steps. The first step was performed at 40ºC for 30 
sec. and the second at 75ºC for 5 min. Coupling reactions were performed at 75ºC using Fmoc 
amino acids in DMF (5 equiv related to the resin), HBTU/HOBT in DMF (5 equiv) and DIEA in 
NMP (10 equiv). 
Acetylation reactions were performed with DIEA (20 equiv) and Ac2O (20 equiv) in DMF for 
1 h or using an Ac2O/DIEA/DMF (1:1:1) solution (4x10 min). 
Cleavage of peptides from the resin, and concomitant side chain deprotection were performed 
using TFA/EDT/H2O/TIPS (94:2.5:2.5:1) (1 ml, 100 mg of resin) at room temperature for 3 h. 
The resin was filtered off and crude products were precipitated with cold Et2O. The resulting 
solid was centrifuged, washed twice with ethyl ether, and then lyophilized.   
Peptides with <80% purity were purified by MPLC using SNAP 12g KP-C18-HS cartridges in 
an ISOLERA ONE (BIOTAGE). A gradient of CH3CN:H2O (0.05% TFA) from 0:100 to 30:70 
over 60 min as mobile phase, and a flux of 5 mL/min were used. Some peptides were purified by 
semipreparative RP-HPLC-MS (Waters 2545) coupled to a mass spectrometer 3100 detector, 
using a SUNFIRE
TM 
column C18 (5µ, 10x150 mm) and a flux of 8 mL/min using the methods 
described in Tables S1-S4. Peptide purity was analyzed using an analytical HPLC: Waters 
(model 2690) with a SUNFIRE
TM 
column C18 (3.5m, 4.6 x 50 mm) at 1 mL/min with a 5 to 50% 
gradient of CH3CN (0.08% HCO2H):H2O (0.01% HCO2H) in 15 min as mobile phase or Agilent 
(model 1120 Compact LC ) with Eclipse Plus column C18  (4.6 x150 mm) at 1.5 mL/min with a 
5 to 50: gradient of CH3CN :H2O (0.05% TFA) in 20 min as mobile phase. Characterization of 
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the products was performed by HPLC-MS (Waters) coupled to a single quadrupole ESI-MS 
(Micromass ZQ 2000). 
Characterization data (HPLC tR and MS) of all library peptides are recorded in Tables S1-S4. 
 
Detailed experimental procedures for the conformational analysis (CD and NMR), and the 
biological experiments are described in the Supporting Information. 
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